SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations
June 23, 2021 SynAct Pharma AB (“SynAct”) today announces that the company has filed two patent applications covering novel salt and crystal forms related to AP1189 and the oral delivery of AP1189 and these novel forms. These novel forms have beneficial and surprising properties and were discovered as a result of ongoing efforts to both optimize the oral dosing of AP1189 and to further enhance the intellectual property surrounding AP1189.“We are excited about the discoveries related to specific salts and their unique crystal forms including unique novel physical and chemical properties”